Table 3 Adverse Events.

From: Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

 

No. of patients (%)

3R/3R (n = 18)

2R/2R + 2R/3R (n = 5 )

Grade 1

Grade 2

Grade 3

Grade 1

Grade 2

Grade 3

Cycle 1 only

 Nausea

2

0

0

1

0

0

 Fatigue

2

0

1

0

0

0

 Diarrhea

1

1

2

1

0

0

 Vomiting

3

2

0

0

1

0

 Anorexia

1

0

0

0

0

0

 Myalgia

0

0

0

1

0

0

 Gastritis

0

1

 

0

0

0

 Mucositis

2

0

1

0

0

0

 Neutropenia

0

2

2

0

0

0

 Hand-foot syndrome

1

1

0

0

0

0

 Rash

1

0

0

0

0

0

 Dry Skin

1

0

0

0

0

0

 Hyperpigmentation

3

0

0

0

0

0

All Cycles

 Nausea

4

0

0

1

0

0

 Fatigue

4

0

2

0

0

0

 Diarrhea

1

1

2

1

0

0

 Vomiting

4

2

0

0

1

0

 Anorexia

2

0

0

0

0

0

 Dyspepsia

1

0

0

0

0

0

 Enterocolitis

0

0

0

0

0

1

 Abdominal Pain

1

0

0

0

0

0

 Myalgia

0

0

0

1

0

0

 Gastritis

0

1

0

0

0

0

 Mucositis

1

0

2

0

0

0

 Neutropenia

0

2

2

0

1

0

 Hand-foot syndrome

4

3

0

0

0

0

 Rash

1

0

0

0

0

0

 Dry Skin

2

0

0

0

0

0

 Hyperpigmentation

3

2

0

2

0

0

 Dental abscess

0

0

1

0

0

0

 Peripheral neuropathy

1

0

0

0

0

0

 Dehydration

0

1

0

0

0

0

  1. One patient did not complete toxicity evaluation for cycle 1 due to rapidly progressive metastatic disease.